Compare Amgen, Inc. (AMGN) vs Prologis Inc (PLD) Price & Performance

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Prologis (PLD) trades at $140.87, down 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.05 exceeding the $0.806 estimate. Fundamentals show robust revenue growth to $8.79B in 2025 and a high net income margin of 41.54%, though valuation ratios like a P/E of 35.39 are elevated. Recent news highlights a rejected $16.9 billion takeover bid for SEGRO, indicating aggressive growth ambitions.

The outlook for PLD is positive, supported by embedded rent growth, a $42B development pipeline, and expansion into data centers. Key risks include rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and integration challenges from potential acquisitions. Analyst sentiment is bullish with 57% buy ratings, but investors should monitor execution on strategic initiatives and macroeconomic impacts on logistics demand.